Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

5.37USD
17 Nov 2017
Change (% chg)

$0.08 (+1.51%)
Prev Close
$5.29
Open
$5.28
Day's High
$5.55
Day's Low
$5.20
Volume
128,113
Avg. Vol
171,665
52-wk High
$15.01
52-wk Low
$4.10

Summary

Name Age Since Current Position

Steven Meyer

60 2017 Independent Chairman of the Board

Saeed Motahari

51 2017 President, Chief Executive Officer, Director

Andrew Long

2017 Chief Financial Officer

Franc Fosse

45 2014 General Counsel, Corporate Secretary

Rohit Vishnoi

2017 Director

Pierre Lapalme

76 2011 Independent Director

Brian Tambi

71 2010 Independent Director

Biographies

Name Description

Steven Meyer

Mr. Steven J. Meyer serves as Independent Chairman of the Board of the Company. has served on our Board since November 2010 and has served as our Chairman of the Board since January 9, 2017. From August 2007 until November 2010, Mr. Meyer served as a director of Insys Pharma. Mr. Meyer has served as a director of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since November 2005, Mr. Meyer has served as the Chief Financial Officer of JVM Realty Corporation, a private investment firm specializing in the acquisition, re-positioning and management of real estate for investors. Prior to that, Mr. Meyer was employed by Baxter International Incorporated, a global healthcare company, where he served as Corporate Treasurer and International Controller and VP of Global Operations during a 23-year career at this company. Mr. Meyer earned his MBA in finance and accounting from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Economics from the University of Illinois in Champaign-Urbana. He is an Illinois Certified Public Accountant.

Saeed Motahari

Mr. Saeed Motahari serves as President, Chief Executive Officer, Director of the company effective April 17, 2017. Prior to joining the Company, Mr. Motahari served as the Chief Commercial Officer of Purdue Pharma L.P. from May 2014 to April 2017. From 2004 to 2014, Mr. Motahari worked at Abbott Laboratories and AbbVie, including serving as Vice President of US Specialty Brands – New Launches. Mr. Motahari also held P&L responsibility for Specialty Franchises in the Renal, Oncology, Endocrinology, Acute Care, Virology and Neuroscience therapeutic areas. Mr. Motahari has also led various commercial organizations at Abbott Laboratories, Bristol-Myers Squibb and Hoffmann-La Roche in managed care, commercial operations, global analytics and new product development. Mr. Motahari received a BS in Biology and holds a Master’s of Business degree from Concordia University, Montreal, Canada.

Andrew Long

Mr. Andrew G. Long serves as Chief Financial Officer of the Company with effective from August 7, 2017. Andrew G. Long is a seasoned finance executive with three decades of experience in the life sciences, bio-pharma and industrial sectors. Mr. Long brings to Insys a diverse set of experiences, which he honed at companies known for grooming best-in-class finance talent. His extensive skillset includes: corporate and operational finance, strategy, supply chain, information technology, M&A integration and talent acquisition and development. He most recently served as Senior Vice President of Global Finance at Patheon, from 2015 to 2017, where he worked extensively with their operational finance and corporate team members on a number of initiatives leading up to Patheon's IPO. Prior to his role at Patheon, Mr. Long spent nine years providing management and financial operations expertise as Vice President of Global Finance for multiple divisions at Thermo Fisher Scientific. He previously spent five years directing global financial planning, reporting and analysis activities for the BioScience Division of Cambrex Corporation. Previously, Mr. Long also spent almost a decade building his financial expertise in various roles at Abbott Laboratories.

Franc Fosse

Mr. Franc Del Fosse serves as General Counsel and Corporate Secretary of the Company since February 1st 2014. Prior to joining the Company, Mr. Del Fosse was a partner at the law firm of Snell & Wilmer L.L.P. He was an attorney at Snell & Wilmer from 2005-2014. From 2001-2005, Mr. Del Fosse was an associate at the law firm of Shearman & Sterling. Mr. Del Fosse holds a J.D. degree from Columbia University School of Law and an undergraduate degree from Arizona State University. He is a member of the State Bar of California and Arizona.

Rohit Vishnoi

Pierre Lapalme

Mr. Pierre Lapalme serves as Independent Director of Insys Therapeutics, Inc. Mr. Pierre has served on our Board since March 2011. Mr. Lapalme is Chairman of the Board of Pediapharm Inc., a publicly traded pharmaceutical company traded on the Toronto Stock Exchange, and has served on their Board of Directors since January 2014. From January 2004 to June 2016, Mr. Lapalme served on the Board of Directors of BioMarin Pharmaceutical Inc., a publicly traded pharmaceutical company. From August 2004 until January 2015, Mr. Lapalme served as Chairman of the Board of Directors of BioMarin Pharmaceutical Inc. From 2009 to 2016, Mr. Lapalme served on the Board of Directors of Aeterna Zentaris, Inc., a biopharmaceutical company publicly traded on the Toronto Stock Exchange. From 1995 until his retirement in 2003, he served as the President and Chief Executive Officer of North America Ethypharm, Inc., a drug delivery company. Throughout his career, Mr. Lapalme held numerous senior management positions in the pharmaceutical industry, including Chief Executive Officer and Chairman of the Board of Rhône-Poulenc Pharmaceuticals, Inc., in Canada, from 1979 to 1994, and Senior Vice President and General Manager of North America Ethicals, a division of Rhône-Poulenc Rorer, Inc. (now known as Sanofi) where he oversaw the development of the ethical pharmaceutical business in the United States, Canada, Mexico, and Central America. Mr. Lapalme served on the board of the National Pharmaceutical Council and was a board member of the Pharmaceutical Manufacturers Association of Canada, where he played a leading role in reinstituting certain patent protection for pharmaceuticals. Mr. Lapalme also previously served on the board of directors of two other public companies: Sciele Pharmaceuticals Inc. from 2000 to 2008 and Bioxel Pharma from 2004 to 2009. He also served on the board of two private biotech companies. Mr. Lapalme studied at the University of Western Ontario and INSEAD France.

Brian Tambi

Mr. Brian Tambi serves as Independent Director of Insys Therapeutics, Inc. Brian Tambi has served on our Board since November 2010. From August 2007 until the November 2010, Mr. Tambi served as a director of Insys Pharma. Mr. Tambi has served as a member of the Board of Directors of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since forming the company in January 2006, Mr. Tambi has served as the Chairman of the Board, President and Chief Executive Officer of Antrim Pharma (formerly BrianT Laboratories LLC), a pharmaceutical company currently focused on developing, manufacturing and marketing combinations of leading single agent drugs and delivery systems. From 1995 to January 2007, Mr. Tambi served as the Chairman, President and Chief Executive Officer of Morton Grove Pharmaceuticals, Inc. Prior to Morton Grove, Mr. Tambi served as President of Ivax North American Pharmaceuticals and as a member of the board of directors of Ivax Corporation (acquired by Teva), a publicly traded pharmaceutical company. Mr. Tambi also served as Chief Operating Officer of Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. Mr. Tambi also held executive positions at Lyphomed, Inc. and Bristol-Myers Squibb. Mr. Tambi earned his MBA in International Finance & Economics and his B.S. in Corporate Finance from Syracuse University.

Basic Compensation

Name Fiscal Year Total

Steven Meyer

306,428

Saeed Motahari

--

Andrew Long

--

Franc Fosse

665,926

Rohit Vishnoi

--

Pierre Lapalme

299,428

Brian Tambi

266,428
As Of  31 Dec 2016

Options Compensation